ESSA Pharma
Vancouver
About ESSA Pharma
ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with a focus on advanced prostate cancer. ESSA is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR N-terminal domain is an ideal target for next-generation hormone therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $280.7M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2022)
- Ticker: cve:EPI
- Website: essapharma.com
- Phone: (832) 831-5958
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/essa-pharma-177568 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.